CONTEXT:  Commercially sponsored announcement of a retrospective study published in Journal of Urology looking at the impact of late luteinizing hormone-releasing hormone agonist dosing on testosterone suppression in patients with prostate cancer.  The study is a follow up to previous research and looks at the effects of the drug on circulating testosterone levels – the aim being to reduce testosterone to castration levels to deprive the cancer of “fuel”.  This therapy, called androgen deprivation therapy is standard of care for advanced prostate cancer | US data only.

IMPACT:  Medium

READ TIME:  4 mins


Quality Level Mean [1 – 10]:  7

1. “BUFFALO GROVE, Ill., April 12, 2021 /PRNewswire/ — Tolmar Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, announced the publication of a manuscript entitled “Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere – An Analysis of US Clinical Data” in the February issue of Journal of Urology.” 

2. “This retrospective analysis of real-world data is a more detailed follow-up of the results to “The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data,” which was published in the April 2020 issue of Journal of Urology.” 

3. “”This new study reflects Tolmar’s ongoing commitment to furthering research on the treatment of advanced prostate cancer through peer-reviewed publications,” said David Crawford, M.D., Clinical Professor of Urology, University of California San Diego. This study was supported by Tolmar Pharmaceuticals, Inc.” 

4. “The Company’s lead product, ELIGARD®, is a luteinizing hormone releasing hormone (LHRH) agonist indicated for the treatment of advanced prostate cancer.” 

5. “ELIGARD causes an increase in testosterone during the first few weeks of therapy and some men may experience new or worsening symptoms of prostate cancer e.g., bone pain, urinary symptoms, or nerve problems such as numbness, during this period.” 

Source URL: https://www.prnewswire.com/news-releases/tolmar-publishes-study-in-the-february-issue-of-journal-of-urology-on-the-impact-of-late-dosing-on-testosterone-suppression-with-two-different-leuprolide-acetate-formulations-in-situ-gel-and-microsphere–an-analysis-of-us-clinic-301266673.html

URL2: https://www.auajournals.org/doi/10.1097/JU.0000000000001392